Anterior uveitis
Drug research and approvals for anterior uveitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 30 studies of anterior uveitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 30
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 0
- Gryrotonic Training in Behcet-diseased Elders With Breast CancerNCT07929116 · Not applicable · Cairo University · starts Nov 30, 2026
- PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCTNCT07813598 · Not reported · Sheffield Children's NHS Foundation Trust · starts Sep 9, 2026
- Diet Restiction in Subjects With Behcet Disease and Complaint of TinnitusNCT07702149 · Not applicable · Cairo University · starts Jun 4, 2026
- Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet DiseaseNCT07702123 · Not applicable · Cairo University · starts Jun 2, 2026
- Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle TrianingNCT07662603 · Not applicable · Cairo University · starts May 6, 2026
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIUNCT07552012 · Phase 2 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · starts Jan 29, 2026
- Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet DiseaseNCT07375940 · Not applicable · Meyer Children's Hospital IRCCS · starts Jan 12, 2026
- Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy…NCT07276087 · Not reported · ÖZLEM NUR TOK YAMAN · starts Sep 11, 2025
- Ustekinumab in BEhçet's Syndrome STudyNCT07244614 · Not reported · Groupe français d'étude des Maladies Inflammatoires de loeil · starts Sep 1, 2025
Approved 2
- DifluprednateGlucocorticoid receptor agonist
- Loteprednol etabonateGlucocorticoid receptor agonist
Phase 3 6
- Prednisolone acetateGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- VoclosporinSerine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
- EthambutolArabinosyltransferase A inhibitor
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- Fluocinolone acetonideGlucocorticoid receptor agonist
Phase 2 4
- GanciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- ValganciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- ValacyclovirHuman herpesvirus 1 DNA polymerase inhibitor
- Licaminlimab
Phase 1 or earlier 2
- SirolimusFK506-binding protein 1A inhibitor
- Interferon gamma-1bInterferon gamma receptor agonist
How its trials ended
50 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 83% met their primary endpoint, 0% missed it and 17% stopped early.
- Completed, result not reported2346%
- Met its primary endpoint1020%
- Status unknown918%
- Ongoing612%
- Stopped: other or unclear24%
| Sep 28, 2018 | HumiraTreatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older | AbbVie, Inc. | Approved |
| Jun 30, 2016 | HumiraIndicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients | AbbVie, Inc. | Approved |
| Jun 13, 2012 | DurezolTreatment of endogenous anterior uveitis | Alcon Pharmaceuticals. Ltd. | Approved |
| Oct 4, 2023 | MethotrexateTreatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitis | Nordic Group B.V. | Designated |
| Jun 22, 2022 | AAV2.adalimumabTreatment of non-infectious intermediate, posterior, or panuveitis or chronic non-infectious anterior uveitis | Kriya Therapeutics, Inc. | Designated |
| Dec 7, 2021 | TacrolimusTreatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis | BioNanoSim Ltd. | Designated |
| Jun 3, 2019 | Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis | Palatin Technologies, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA